Abstract. Vitamin A (VA) has a number of important biological functions in human growth and development. Previous studies by our group demonstrated that the normal VA levels improved recovery of learning and memory function and decreased apoptosis in rats with hypoxic-ischemic brain damage (HIBD). However, it has not been fully elucidated how VA regulates the apoptosis of neuronal cells. To investigate the anti-apoptotic effect of VA, an in vitro oxygen glucose deprivation (OGD) model in PC12 cells was treated with four concentrations of all-trans-retinoic acid (ATRA), an active in vivo product of VA. Following in vitro OGD injury in PC12 cells, the percentage of apoptosis and the fluorescence intensity of the mitochondrial membrane potential (MMP) were increased in the cells, and the expression levels of B-cell lymphoma-associated X (Bax) were enhanced. ATRA treatment at 2-4 µmol/l for 24 h decreased the percentage of apoptosis and the MMP of the PC12 cells injured by OGD. ATRA at 4 µmol/l also reduced the expression levels of Bax and enhanced the expression of B-cell lymphoma 2. Furthermore, RNA interference with retinoic acid receptor α (RARα) reversed the observed effect in PC12 cells following ATRA treatment at 4 µmol/l alone. In conclusion, the present study suggested that treatment with ATRA at 4 µmol/l suppressed apoptosis of PC12 cells following OGD injury, potentially through regulation of the RARα signaling pathway.
Introduction
Vitamin A (VA) is an essential fat-soluble micronutrient. Retinoic acid (RA) is the main active metabolite of VA in vivo, and it exists in three isomers: All-trans-retinoic acid (ATRA), 13-cis-retinoic acid (13-cis-RA) and 9-cis-retinoic acid (9-cis-RA). ATRA is able to regulate the transcriptional activity of downstream target genes through retinoic acid receptor (RAR)-mediated signal transduction. RARs consist of two families, the RARs and the retinoid X receptors (RXRs), with each family composed of three isotypes: α, β and γ. The RARα subtype has an important role in neuronal development (1) (2) (3) .
A previous study by our group identified that neonatal rats with VA deficiency during the gestational period exhibited a reduction in the expression of RARα, coupled with deficits in learning and memory function in adulthood (4) . It has also been demonstrated that a VA deficiency reduces the recovery ability of learning and memory function in pups following hypoxic-ischemic brain damage (HIBD), which is regulated by the RARα signaling pathway (5) . The RARα signaling pathway is activated by ATRA, which triggers a variety of biological functions. Several previous studies investigated the mechanism of apoptosis in neuronal cells and the effect of antagonizing neuronal apoptosis in brain damage (6) (7) (8) (9) (10) (11) (12) (13) (14) . However, whether VA has an anti-apoptotic function and the mechanisms underlying these effects in neuronal cells have remained elusive.
The present study aimed to establish an oxygen and glucose deprivation (OGD) model in vitro to investigate whether ATRA is neuroprotective by suppressing the apoptosis of neuronal cells. It was revealed that ATRA treatment at 4 µmol/l suppresses apoptosis of PC12 cells injured by OGD through the RARα signaling pathway. The study of ATRA may facilitate and promote the clinical application of VA as an adjuvant therapy for patients with brain damage.
All-trans retinoic acid suppresses apoptosis in PC12 cells
injured by oxygen and glucose deprivation via the retinoic acid receptor α signaling pathway 
RNA interference of RARα.
A recombinant adenovirus of RARα-small interfering (si)RNA was designed and constructed in our laboratory (5) . Three types of RARα-siRNA adenovirus were pooled to transfect into PC12 cells for 36 h. A pair of unspecific siRNA was labeled with a red fluorescent protein, RFP, and served as a negative control. The infection efficiency and consistency of Ad-siRARα and Ad-RFP were confirmed using fluorescent microscopy (Nijon TE2000-A; Nikon, Tokyo, Japan).
RNA isolation and quantitative polymerase chain reaction (qPCR) analysis. Total RNA was isolated using an RNA extraction kit (Genemega Inc., San Diego, CA, USA) and reverse-transcribed into cDNA using the PrimeScript ® RT reagent kit (DRR037A; Takara Bio, Inc., Shiga, Japan) using a Bio-Rad My Cycler (Bio-Rad Laboratories, Inc., Hercules, CA, USA) according to the manufacturer's instructions. The single-stranded cDNA was diluted 5-to 10-fold and used as the PCR template. The cDNA was quantified using real-time PCR with the StepOne v2.1 Real-Time PCR instrument (ABI; Redwood City, CA, USA) and RealMasterMix (SYBR Green; Tiangen Biotech Co., Ltd., Beijing, China). The procedure was performed as follows: Denaturation at 95˚C for 10 min, followed by 45 cycles at 95˚C for 15 sec, 60˚C for 60 sec and 72˚C for 30 sec. Melting curve analysis and gel electrophoresis were utilized to ensure that a single PCR product was amplified in each reaction. The PCR primers were designed using Primer Premier 5.0 software (Premier Biosoft International, Paolo Alto, CA, USA). The primer sequences for RARα, B-cell lymphoma 2-associated X (Bax), B-cell lymphoma 2 (Bcl-2) and β-actin are summarized in Table I .
The data were presented as the Ct value and the ratio of the relative quantity of the target gene to β-actin was calculated. A semi-quantitative PCR reaction was conducted using the following protocol: 94˚C for 20 sec, 68˚C for 30 sec and 70˚C for 20 sec for 16 cycles, with a 1˚C decrease per cycle, followed by 25-32 cycles at 94˚C for 20 sec, 56˚C for 30 sec and 70˚C for 20 sec. The PCR products were resolved on 1.5% agarose gels. All of the samples were normalized to the endogenous levels of β-actin. All operations were conducted in accordance with the standard protocol.
Western blot analysis. The cells were collected from dishes or wells and lysed in radioimmunoprecipitation assay (RIPA) buffer containing phenylmethanesulfonyl fluoride (Biotake Co., Ltd., Taiwan, China). The cell lysates were collected and the protein concentration was determined using a bicinchoninic acid protein concentration determination kit (Biotake Co., Ltd., Beijing, China). The cell lysates were purified by 10% SDS-Page (Beyotime, China), with ~20 µg of total protein loaded per lane. Following electrophoresis, the proteins were transferred to an Immobilon-P membrane (Millipore, Billerica, MA, USA). Following blocking with 5% FBS in Tris-buffered saline/Tween-20 (TBST) buffer at room temperature for 1 h, the membrane was probed overnight with the primary antibodies, goat polyclonal anti-RARα (28767; 1:200-1:2,000; Abcam, Cambridge, MA, USA), mouse monoclonal anti-Bax (B8429; 1:30-1:200; Sigma), mouse monoclonal anti-Bcl-2 (sc-7382; 1:100-1:1,000; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and mouaw monoclonoal β-actin (sc-130065; 1:100-1:1,000; Santa Cruz Biotechnology, Inc.), respectively, at 4˚C and was then incubated with the appropriate secondary antibody conjugated with horseradish peroxidase (Santa Cruz Biotechnology, Inc.) at room temperature for 1 h. The protein was detected using an enhanced chemiluminescent substrate kit of chemiluminescent HRP substrate (Millipore, Billerica, MA, USA) and recorded using a Kodak 440CF Image Station (Kodak, Rochester, NY, USA). Measurement of apoptosis. The apoptotic rate of the PC12 cells was determined using an Annexin V-enhanced green fluorescent protein (EGFP)/propidium iodide (PI) Apoptosis Detection kit (KGA103; KeyGen Biotech, Nanjing, China) and flow cytometric analysis. Following OGD treatment, the cells were collected, washed twice with cold PBS and resuspended in 400 µl of 1X Annexin V binding buffer at a concentration of ~1x10 6 cells/ml. A total of 5 µl of Annexin V-EGFP solution was added to the cell suspension and incubated for 15 min at 2-8˚C in the dark. Next, 10 µl of PI was added to the mixture for 5 min. The stained cells were analyzed using flow cytometry (FacsCalibur; BD Biosciences, Franklin Lakes, NJ, USA) within 1 h. Annexin V labeled with a fluorophore identified cells at the early stage of apoptosis, and PI, a fluorescent nucleic acid binding dye, stained cells in the middle and late stages of apoptosis. The apoptotic rate was calculated as the percentage of Annexin V-positive and PI-negative cells divided by the total number of cells in the imaged region.
Measurement of the mitochondrial membrane potential (MMP).
The MMP change of the PC12 cells was measured using a mitochondrial membrane potential assay kit with JC-1 (C2006; Beyotime Institute of Biotechnology, Shanghai, China) and flow cytometric analysis. JC-1 is widely used as a fluorescent probe to detect the MMP. When the MMP is high, the dye assembles in a dimeric configuration in the mitochondrial matrix and emits a red fluorescent signal. When the MMP is low, the dye exists in a monomeric configuration and emits a green fluorescent signal. 
Statistical analysis.
Values are expressed as the mean ± standard error of measurements. Significant differences between samples were analyzed using a one-way analysis of variance (ANOVA), a repeated-measures ANOVA and the Student-Newman-Keuls test (SNK-q). All statistical analyses were computed using GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, CA, USA) software by professional staff. P≤0.05 was considered to indicate a statistically significant difference.
Results
Construction of an OGD model in PC12 cells. The PC12 cell line was derived from transplantable rat pheochromocytoma. The PC12 cells in culture exhibited clearly visible spindle-or oval-shaped cell bodies, while they exhibited shrinkage, light refraction with decreased, chrysanthemum-like cell body shrinkage and an increase in floating cells following injury with OGD when compared with the normal PC12 cells (Fig. 1A) . Flow cytometric analysis indicated that the apoptotic rate of PC12 cells following OGD treatment increased to 18.51±1.42%, which was significantly different from that in the uninjured group (8.08±0.90%; Fig. 1B and C). Flow cytometry was also used to analyze the changes in the MMP in the PC12 cells. It was identified that the percentage of green fluorescence intensity of JC-1 in PC12 cells also significantly increased, from 4.14±1.47% in the untreated group to 14.47±3.73% in the OGD-injured group ( Fig. 1D and E) , suggesting that OGD injury decreased the MMP in PC12 cells. The mRNA and protein expression of apoptosis-associated-factor Bax was upregulated following ODG injury. The mRNA expression of anti-apoptotic factor Bcl-2 in the OGD-injured group was marginally increased when compared with the uninjured group (Fig. 1F) ; however, the protein expression of Bcl-2 was not significantly different (Fig. 1G) . These data demonstrated that the OGD model in vitro effectively induced apoptosis of PC12 cells.
Effect of ATRA treatment on PC12 cells injured by OGD.
To examine the effect of ATRA, the PC12 cells were pretreated with four different concentrations prior to OGD injury. As revealed in Fig. 2A , the apoptotic rate of PC12 cells following OGD was 14.01±1.26 and 11.48±1.53% in the 2 and 4 µmol/l ATRA groups, respectively, which was significantly decreased compared with the OGD-treated group (P<0.05). However, the apoptotic rate of the 0.5 µmol/l ATRA-treated group was equal to that of the OGD-treated group, whereas the ratio was significantly increased following 20 µmol/l ATRA treatment (P<0.05). The percentage of green fluorescent intensity reversely indicating MMP levels was in parallel with the changes in apoptotic rates (Fig. 2B) . Pretreatment with 4 µmol/l ATRA increased the MMP and decreased the apoptotic rate to a greater extent than 2 µmol/l ATRA; however, the differences were not statistically significant. The 4 µmol/l ATRA treatment was determined to be the optimal anti-apoptotic concentration of ATRA to use RARα mRNA and protein expression levels are altered following OGD treatment with ATRA at 4 µmol/l. To examine the effects of ATRA on PC12 cells, the changes in RARα expression levels were detected by qPCR and western blot analysis (Fig. 3) . The mRNA expression of RARα in OGD-injured PC12 cells increased following treatment with 4 µmol/l ATRA, whereas the expression decreased following OGD injury without any other treatment. The protein expression levels of RARα in OGD-injured PC12 cells treated with 4 µmol/l ATRA were higher than those in OGD-injured cells without ATRA treatment. This finding suggested that the levels of RARα expression are affected by OGD and 4 µmol/l ATRA, and that RARα is involved in ATRA-mediated signaling during OGD.
Anti-apoptotic effect of 4 µmol/l ATRA. To examine the anti-apoptotic effect of 4 µmol/l ATRA, the expression of apoptosis-associated factors was examined. As revealed in Fig. 4A , when compared with the OGD-injured cells without ATRA treatment, the mRNA expression of Bax was significantly reduced by 4 µmol/l ATRA treatment following OGD injury (P<0.05). Furthermore, the mRNA expression of Bcl-2 was significantly increased in the 4 µmol/l ATRA+OGD (Fig. 5A ). Following transfection with Ad-siRARα, the percentages of apoptotic cells and the green fluorescence intensity reversely correlated with the MMP were significantly higher than those of the Ad-RFP group following 4 µmol/l ATRA+OGD treatment ( Fig. 5B and  C) . Furthermore, the PC12 cells transfected with Ad-siRARα had increased mRNA expression levels of Bax and decreased mRNA expression levels of Bcl-2 following the 4 µmol/l ATRA+OGD treatment (Fig. 5D ). The changes in Bax and Bcl-2 protein expression were similar to the changes in mRNA expression in the PC12 cells transfected with Ad-siRARα and treated with 4 µmol/l ATRA+OGD (Fig. 5E ). These data indicated that pre-treatment with 4 µmol/l ATRA suppressed apoptosis in OGD-injured PC12 cells through the RARα signaling pathway.
Discussion
Vitamin A is an essential fat-soluble micronutrient that contributes to development and growth. RA, which includes ATRA, 13-cis-retinoic acid (13-cis-RA) and 9-cis-retinoic acid (9-cis-RA), is a main active metabolite of VA in vivo. ATRA can regulate the transcriptional activity of downstream genes through retinoic acid nuclear receptor-mediated signal transduction. VA deficiency during pregnancy downregulates the expression of RARα and NR1 through Ca 2+ signaling and decreases the learning and memory function of offspring (4). Jacobs et al (15) found that RA promotes neurogenesis and that RA deficiency leads to lower survival of nerve cells in vivo. RA also affects the proliferation and apoptosis of damaged nerve cells (16) . Shinozaki et al (17) found that precursor nerve cells differentially weakened in the hippocampal dentate gyrus granule cell layer if RA was deprived in adult rats. However, the regulatory effects of VA on the anti-apoptotic mechanisms of neuron cells remain elusive.
In the present study, an in vitro OGD model in PC12 cells was successfully established, which exhibited an increase in the percentage of apoptosis and a decrease in the levels of MMP, but also significantly enhanced levels of Bax expression. These results demonstrated that OGD damage leads to acute apoptosis in PC12 cells. Furthermore, it was identified that 2 and 4 µmol/l ATRA significantly suppressed the apoptosis of PC12 cells injured by OGD and effectively maintained MMP stability. In addition, 4 µmol/l ATRA upregulated Bcl-2 expression and downregulated Bax expression. However, 0.5 µmol/l ATRA was not able to reverse the apoptosis that occurred in OGD-injured PC12 cells due to its low concentration, and 20 µmol/l ATRA produced increased levels of apoptosis in PC12 cells due to toxicity at such a high concentration. These results indicated that ATRA had different biological effects at different concentrations. Numerous studies have demonstrated that ATRA is correlated with apoptosis (18) (19) (20) (21) . In the present study, 4 µmol/l ATRA treatment more effectively suppressed apoptosis in the PC12 cells following OGD treatment and it was optimal to further reveal the mechanism of ATRA regulation.
ATRA receptors include two types, RARs and RXRs, which both contain three subtypes (α, β and γ). Most commonly, these receptors form homo-or heterodimers that combine with region-specific RARs elements (RARE) in the promoter region of a target gene to regulate its transcription. RARα is a main receptor in hippocampal development in the rat, particularly in learning and memory function. A previous in vivo study by our group demonstrated that VA levels affect learning and memory function via the RARα pathway (22) . In the present study, OGD injury decreased the levels of RARα expression in PC12 cells, and the expression of RARα increased when ATRA was added to PC12 cells following OGD treatment, suggesting that the ATRA signaling pathway may regulate apoptosis following OGD damage. Katsuki et al (23) demonstrated that ATRA upregulates RARα expression and enhances BDNF reactivity to protect the dopaminergic neural system from damage.
To confirm a regulatory role of RARα, an Ad-siRARα recombinant adenovirus was used. It was revealed that Ad-siRARα significantly blocked RARα expression in PC12 cells following ATRA and OGD treatment. In PC12 cells subjected to ATRA and OGD treatment, inhibition of RARα significantly increased the percentage of apoptosis, decreased the MMP, and also upregulated Bax expression and downregulated Bcl-2 expression. These findings demonstrated that the anti-apoptotic properties of ATRA may be regulated through the RARα signaling pathway. Therefore, future studies will focus on the regulatory effect of RARα on the anti-apoptotic Bcl-2 gene and the pro-apoptotic Bax gene.
In conclusion, an in vitro OGD model in PC12 cells was successfully established in the present study. Pretreatment with ATRA at a concentration of 2-4 µmol/l had an anti-apoptotic effect on OGD-injured PC12 cells via the RARα signaling pathway, suggesting a new method of adjuvant therapy for patients with brain damage.
